{
  "source": "PA-Notification-Livmarli.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1373-5\nProgram Prior Authorization/Notification\nMedication Livmarli™ (maralixibat)\nP&T Approval Date 11/2021, 11/2022, 5/2023, 5/2024, 9/2024\nEffective Date 12/1/2024\n1. Background:\nLivmarli (maralixibat) is an ileal bile acid transporter inhibitor indicated for the treatment of\ncholestatic pruritis in patients 12 months of age and older with progressive familial intrahepatic\ncholestasis (PFIC). Livmarli is also indicated for the treatment of cholestatic pruritis in patients\n3 months of age and older with Alagille syndrome (ALGS).\nLimitation of Use:\nLivmarli is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11\nvariants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein.\n2. Coverage Criteriaa:\nA. Progressive Familial Intrahepatic Cholestasis\n1. Initial Authorization\na. Livmarli will be approved based upon both of the following criteria:\n(1) Diagnosis of progressive familial intrahepatic cholestasis (PFIC)\n-AND-\n(2) Patient is experiencing pruritus associated with PFIC.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Livmarli will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Livmarli therapy\nAuthorization will be issued for 12 months.\nB. Alagille Syndrome\n1. Initial Authorization\na. Livmarli will be approved based upon both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of Alagille syndrome (ALGS).\n-AND-\n(2) Patient is experiencing pruritus associated with ALGS.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Livmarli will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Livmarli therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage cr",
    "o Livmarli therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Livmarli [package insert]. Foster City, CA: Mirum Pharmaceuticals, Inc.; July 2024.\nProgram Prior Authorization/Notification - Livmarli (maralixibat)\nChange Control\n11/2021 New program\n11/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n5/2023 Updated background with expanded indication in ALGS patients 3\nmonths of age and older. No change to coverage criteria. Updated\nreference.\n5/2024 Annual review. Added coverage criteria for new PFIC indication.\nUpdated initial authorization duration to 12 months for ALGS\nindication. Updated background and reference.\n9/2024 Updated background with expanded PFIC indication in patients 12\nmonths to 4 years of age. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}